Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 10/20 | 0.70 |
| ▸ | PRKDC | P78527 | 4/20 | 0.70 |
| ▸ | NEK2 | P51955 | 4/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8307717 | 0.88 | ATR (0.69) | ATRPRKDCNEK2CHEK1PARP1 | |
| SCHEMBL3460862 | 0.85 | ATR (0.72) | ATRPRKDCGSK3BPRKCAPRKCQ | |
| SCHEMBL23703073 | 0.84 | ATR (0.67) | ATRPRKDCMAP4K4ATM | |
| SCHEMBL30048631 | 0.84 | ATR (0.67) | ATRPRKDCMAP4K4ATM | |
| SCHEMBL2484387 | 0.82 | ATR (1.00) | ATRPRKDCATM | |
| SCHEMBL11908281 | 0.82 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL318797 | 0.82 | ATR (0.68) | ATRPRKDCATM | |
| SCHEMBL11909602 | 0.81 | MAP4K4 (0.50) | ATRPRKDCNEK2MAP4K4 | |
| SCHEMBL11906967 | 0.81 | ATR (0.67) | ATRPRKDCMAP4K4PARP1ATM | |
| SCHEMBL3983358 | 0.81 | ATR (0.67) | ATRPRKDCMAP4K4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ATR 423/4885PRKDC 9/4885NEK2 486/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ATR 423/4885PRKDC 9/4885NEK2 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.